Stockscreener 앱 받기
12.20
0.08%
-0.01
시간 외 거래:
12.20
전일 마감가:
$12.21
열려 있는:
$12.25
하루 거래량:
871.44K
Relative Volume:
1.09
시가총액:
$904.53M
수익:
$97.36M
순이익/손실:
$-172.42M
주가수익비율:
-5.308
EPS:
-2.2984
순현금흐름:
$-188.84M
1주 성능:
+2.61%
1개월 성능:
+8.73%
6개월 성능:
-26.28%
1년 성능:
+34.81%
1일 변동 폭
$11.90
$12.36
1주일 범위
$11.56
$12.60
52주 변동 폭
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.20 | 905.27M | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-29 | 업그레이드 | Barclays | Underweight → Overweight |
| 2025-09-17 | 재개 | Barclays | Underweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
[144] Xencor Inc SEC Filing - Stock Titan
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution - Yahoo Finance
Xencor Inc Stock (US98401F1057): Analyst Views In Focus After Recent Collaboration Momentum - AD HOC NEWS
Understanding Momentum Shifts in (XNCR) - Stock Traders Daily
Xencor (XNCR) Slides 2% as Biotech Sentiment Weakens — Support TestedTRIN Signal - newsline.com
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial - MSN
Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20 - AD HOC NEWS
XNCR Technical Analysis & Stock Price Forecast - Intellectia AI
XNCR Q1 2026 Earnings: Deep Loss Miss as Pipeline Biotech Faces Market SkepticismInterim Report - The Legal Advocate
XNCR Q1 2026 Earnings: Significant EPS Miss Amidst Clinical Development ProgressAnnual Report - newsline.com
XNCR Q1 2026 Earnings: Deeper-than-Expected Loss Highlights Persistent R&D InvestmentEarnings Revision Upgrade - newsline.com
Xencor Inc stock (US98401F1057): shares trade around recent lows as investors digest pipeline and va - AD HOC NEWS
Avoiding Lag: Real-Time Signals in (XNCR) Movement - Stock Traders Daily
XNCR Q1 2026 Earnings: Large EPS Miss Amid Pre-Revenue Status; Stock Gains SlightlyEarnings Acceleration Picks - newsline.com
Xencor Inc. (XNCR) Holds Ground Near $11.31: Key Levels in FocusComposite Profile - Newser
Jefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. (XNCR) Competitors - Meyka
Xencor Inc. (XNCR) Holds Near Support as Biotech Sector Shows Mixed SignalsCrowd Entry Points - Newser
Xencor (XNCR) Q1 2026 Underperforms: Key Challenges AheadPro Level Trade Signals - Newser
Xencor’s SWOT analysis: biotech stock faces pipeline execution test - Investing.com
Xencor’s SWOT analysis: biotech stock faces pipeline execution test By Investing.com - Investing.com Canada
Xencor (XNCR) Q1 2026 Disappoints — EPS $-1.71 Below $-0.79 ViewsPopular Trader Picks - Newser
T-cell Engagers Market to Record US$ 58.04 billion by 2035., - openPR.com
Xencor Inc stock (US98401F1057): JPMorgan lifts target while investors eye Q1 2026 update - AD HOC NEWS
Xencor, Inc. $XNCR Shares Sold by UBS Group AG - MarketBeat
EcoR1 reports 2.9% Xencor stake (NASDAQ: XNCR) - Stock Titan
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Xencor stock (US98401F1057): Biotech focus on immunotherapy and protein engineering - AD HOC NEWS
Xencor (XNCR) Declines -2.50% Amid Market Weakness 2026-05-14Undervalued Stocks - Newser
TradingKey - TradingKey
Xencor stock (US98401F1057): Biotech innovator in antibody therapies - AD HOC NEWS
Xencor Is Maintained at Neutral by JP Morgan - Moomoo
TD Cowen Maintains Xencor(XNCR.US) With Buy Rating - Moomoo
J.P. Morgan Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $14 - Moomoo
Xencor (NASDAQ:XNCR) Price Target Raised to $14.00 at JPMorgan Chase & Co. - MarketBeat
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts - simplywall.st
XNCR (Xencor) crushes Q4 estimates with 85% earnings surprise, revenue rises 13.7%, shares jump 4.5%.Open Signal Network - Newser
Xencor (NASDAQ:XNCR) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Xencor (XNCR) Receives a Buy from Wells Fargo - The Globe and Mail
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat - Yahoo Finance
Xencor (NASDAQ:XNCR) Downgraded by Zacks Research to "Strong Sell" - MarketBeat
Xencor, Inc. (XNCR) Stock Analysis: Exploring A 132% Potential Upside In Biotech - DirectorsTalk Interviews
What Xencor (XNCR) is doing to earn customer loyalty (Falls Hard) 2026-05-08Double EMA - newsline.com
MSN Money - MSN
Number of shareholders of Xencor, Inc. – MUN:XE9 - TradingView
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Xencor (NASDAQ:XNCR) Releases Earnings Results, Misses Estimates By $1.06 EPS - MarketBeat
Earnings Flash (XNCR) Xencor, Inc. Reports Q1 Revenue $4.5M - marketscreener.com
Xencor: Q1 Earnings Snapshot - marketscreener.com
Xencor (NASDAQ: XNCR) posts deeper Q1 2026 loss amid royalty dispute and Zenas write-down - Stock Titan
Xencor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):